--- title: "Apollomics (APLM) news: convertible notes" url: "https://aibio.space/companies/apollomics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "APLM convertible notes news: Apollomics signs $2.0 million convertible note with its chairman and CEO. Apollomics, Inc. (NASDAQ: APLM), United States." --- APLM Apollomics, Inc. NASDAQ · United States # Apollomics (APLM) news APLM convertible notes news Listings · 2026-07-14 ## [Apollomics regains Nasdaq compliance on $35 million market value rule](https://aibio.space/news/apollomics-regains-nasdaq-compliance-35-million-market-value-rule/) Nasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026. ## Latest Apollomics news 1. 2026-04-01 Debt Financing [Apollomics signs $2.0 million convertible note with its chairman and CEO](https://aibio.space/news/apollomics-signs-2-0-million-convertible-note-chairman-ceo/) Apollomics signed a $2.0 million unsecured note with its chairman and chief executive, Hung-Wen (Howard) Chen, on March 30, 2026, at 0% interest, which converts into equity at a 20% discount if the company later raises at least $10.0 million. 2. 2025-12-22 Listings [Apollomics interim report shows $4,398 thousand shareholders' deficit at June 30, 2025](https://aibio.space/news/apollomics-interim-report-shows-4-398-thousand-shareholders-deficit/) Apollomics reports a $4,398 thousand shareholders' deficit at June 30, 2025, after cash fell to $2,094 thousand from $9,766 thousand at year-end and the six months produced a $12,536 thousand loss. ## Apollomics at a glance - **Ticker**: APLM - **Listing**: NASDAQ - **Country**: United States ### Related companies - [Dyadic International](https://aibio.space/companies/dyadic-international/) NASDAQ: DYAI - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) NASDAQ: ACOG - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Celcuity](https://aibio.space/companies/celcuity/) NASDAQ: CELC - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) NASDAQ: BRTX - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT ### Also on NASDAQ - [LivaNova](https://aibio.space/companies/livanova/) LIVN - [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) AKTS - [Cytosorbents](https://aibio.space/companies/cytosorbents/) CTSO - [TriSalus Life Sciences](https://aibio.space/companies/trisalus-life-sciences/) TLSI - [Universe Pharmaceuticals](https://aibio.space/companies/universe-pharmaceuticals/) UPC - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) ABVC ## Questions about Apollomics Has Apollomics sold convertible notes? Our latest story on this, dated Apr 1, 2026: "Apollomics signs $2.0 million convertible note with its chairman and CEO". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/apollomics-signs-2-0-million-convertible-note-chairman-ceo/). What is the ticker symbol of Apollomics? Apollomics, Inc. trades under the ticker APLM on NASDAQ. Where is Apollomics listed? Apollomics, Inc. is listed on NASDAQ. What is the SEC CIK of Apollomics? The SEC Central Index Key (CIK) for Apollomics, Inc. is 1944885. Its filings are on SEC EDGAR. How many shares does Apollomics have outstanding? 2,196,052 shares as of 2026-04-24, per the cover page of its 20-F filed 2026-04-24. Which country or territory is Apollomics listed under? Our directory records Apollomics, Inc. under United States. What does Apollomics do? Our directory classifies Apollomics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Apollomics? The ISIN recorded for Apollomics, Inc. is KYG0411D1236. Does aibio.space cover Apollomics? aibio.space lists Apollomics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Apollomics incorporated? SEC records list its state or country of incorporation as E9. What is the latest Apollomics (APLM) stock news? Our latest story on Apollomics, dated Jul 14, 2026: "Apollomics regains Nasdaq compliance on $35 million market value rule". Nasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026. [Source](https://aibio.space/news/apollomics-regains-nasdaq-compliance-35-million-market-value-rule/). How long will Apollomics's cash last? From our story of Dec 22, 2025: The notes say that, based on cash and cash equivalents of $2.1 million at June 30, 2025, the group estimates it may not have sufficient liquidity to continue as a going concern through at least June 30, 2026. [Source](https://aibio.space/news/apollomics-interim-report-shows-4-398-thousand-shareholders-deficit/). How much cash does Apollomics have? From our story of Dec 22, 2025: On November 19, 2025 the group agreed to resolve legal proceedings brought in the Grand Court of the Cayman Islands by two minority investors, paying $5.0 million in cash and approximately $0.9 million in associated legal expenses. [Source](https://aibio.space/news/apollomics-interim-report-shows-4-398-thousand-shareholders-deficit/). Is Apollomics at risk of delisting? Our latest listing story, dated Jul 14, 2026: "Apollomics regains Nasdaq compliance on $35 million market value rule". Nasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026. [Source](https://aibio.space/news/apollomics-regains-nasdaq-compliance-35-million-market-value-rule/). Is Apollomics a smaller reporting company? SEC records list Apollomics, Inc.'s filer category as: Non-accelerated filer
Emerging growth company. ## Investor discussion: Apollomics Members talk about Apollomics (APLM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Apollomics, newest first. Each line links the filing it comes from. 1. 2026-07-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312526302494/d31896dex991.htm) 2. 2026-06-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312526281262/d137400dex991.htm) 3. 2026-04-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312526177357/aplm-20251231.htm) 4. 2026-04-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312526138117/d142784dex991.htm) 5. 2025-12-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312525328822/aplm-ex99_1.htm) 6. 2025-10-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312525240576/d36995dex991.htm) 7. 2025-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312525217820/d58766dex991.htm) 8. 2025-04-03 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000095017025050508/aplm-ex99_1.htm) 9. 2024-12-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312524274340/d834443dex991.htm) 10. 2024-11-14 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312524258804/d912284d6k.htm) 11. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1944885/000119312524249835/d898189dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:APLM on TradingView](https://www.tradingview.com/symbols/NASDAQ-APLM/). ## SEC filings and registration - **SEC name**: Apollomics Inc. - **CIK**: 1944885 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: APLM (Nasdaq), APLMW (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 668 ARROW GRAND CIR, COVINA, CA, 91772 - **Phone**: 1-650-209-4055 - **Shares outstanding**: 2,196,052 as of 2026-04-24 (20-F filed 2026-04-24) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526345197/d133013d6k.htm) filed 2026-08-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526310154/d135604d6k.htm) filed 2026-07-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526302494/d31896d6k.htm) filed 2026-07-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526281262/d137400d6k.htm) filed 2026-06-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526179094/aplm-6k-apr26.htm) filed 2026-04-27 - [20-F](https://www.sec.gov/Archives/edgar/data/1944885/000119312526177357/aplm-20251231.htm) filed 2026-04-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312526138117/d142784d6k.htm) filed 2026-04-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1944885/000119312525328822/aplm-20250630.htm) filed 2025-12-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001944885), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Apollomics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker APLM, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Apollomics, Inc. - **Ticker**: APLM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: KYG0411D1236 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-APLM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/apollomics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Apollomics (APLM) news: convertible notes", 2026-10-31, https://aibio.space/companies/apollomics/